Clinical Trials Logo

Mixed Dyslipidemia clinical trials

View clinical trials related to Mixed Dyslipidemia.

Filter by:

NCT ID: NCT01256476 Completed - Mixed Dyslipidemia Clinical Trials

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia

PREVAIL-US
Start date: October 2010
Phase: Phase 4
Study type: Interventional

Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed dyslipidemia.

NCT ID: NCT01228019 Terminated - Clinical trials for Hypercholesterolemia

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Start date: December 2010
Phase: N/A
Study type: Observational

This survey is being conducted to assess the safety and efficacy of niacin (+) laropiprant (TREDAPTIVE) in usual practice in Korea according to the new product re-examination regulations of the Korean Food and Drug Administration.

NCT ID: NCT00678743 Active, not recruiting - Mixed Dyslipidemia Clinical Trials

An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin

Start date: August 2007
Phase: Phase 4
Study type: Interventional

The primary objective of this trial is to assess the continued efficacy of Omacor co-administered with simvastatin for lowering non-high-density lipoprotein cholesterol (non-HCL-C) levels.

NCT ID: NCT00639158 Completed - Clinical trials for Coronary Heart Disease

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.

NCT ID: NCT00491530 Completed - Mixed Dyslipidemia Clinical Trials

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Start date: June 2007
Phase: Phase 3
Study type: Interventional

The objective of the study is to assess the continued safety of the daily coadministration of ABT-335 in combination with rosuvastatin calcium, simvastatin or atorvastatin calcium.

NCT ID: NCT00487591 Completed - Mixed Dyslipidemia Clinical Trials

An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia

Start date: November 2006
Phase: Phase 4
Study type: Observational

The primary objective of this study is to compare the effect of simvastatin plus Omacor to simvastatin plus placebo for lowering non-high density lipoprotein cholesterol in subjects with mixed dyslipidemia.

NCT ID: NCT00479882 Completed - Clinical trials for Primary Hypercholesterolemia

MK-0524B Lipid Study (MK-0524B-063)

Start date: June 15, 2007
Phase: Phase 3
Study type: Interventional

This is a 20-week clinical trial in participants with primary hypercholesterolemia or mixed dyslipidemia to demonstrate the effect of MK-0524B compared to MK-0524A + Simvastatin on lipid values.

NCT ID: NCT00479388 Completed - Clinical trials for Primary Hypercholesterolemia

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Start date: July 2007
Phase: Phase 3
Study type: Interventional

This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.

NCT ID: NCT00465088 Completed - Hyperlipidemia Clinical Trials

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

SUPREME
Start date: April 2007
Phase: Phase 3
Study type: Interventional

To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating effects at Week 12 in subjects with type II hyperlipidemia or mixed dyslipidemia who are currently off lipid-modifying therapy. This was a prospective, randomized, open-label, blinded endpoint (PROBE) study.

NCT ID: NCT00309712 Completed - Clinical trials for Type II Diabetes Mellitus

Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study

Start date: August 2002
Phase: N/A
Study type: Interventional

The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy.